摘要
背景:在中国,结核病(TB)是威胁生命的疾病,并且新的治疗药物和治疗方案治疗结核病是迫切需要的。 目的:在这项研究中,DNA疫苗表达结核分枝杆菌(MTB)构建了 Rv1419抗原,并对其免疫原性和治疗效果进行了评价。 方法:正常小鼠和结核病模型小鼠肌肉分别每隔两个星期注射免疫和生理盐水三次,质粒载体 pVAX1, M. vaccae vaccine, pVAX1- ag85a (rv3804c) DNA 或者 pVAX1-rv1419 DNA。 结果:在三周最后一次免疫后,流式细胞仪检测表明,与生理盐水组和向量组(P<0.05)相比,较高比例的CD4 + T细胞表达IFN-γ(Th1)响应rv1419蛋白在血液从pVAX1 - rv1419 DNA组,表明主导Th1型免疫应答。相比生理盐水对照组,活菌量肺和脾脏均低于0.41 log10的pVAX1 - rv1419 DNA组。此外,DNA疫苗组肺部的病理变化较少。这些结果表明,pVAX1 - rv1419 DNA可为结核病的治疗是有效的,显著增加Th1型细胞免疫反应,抑制结核杆菌的生长 结论:因此pVAX1 - rv1419 DNA是一个可行结核病治疗组合DNA疫苗中的包涵体组成成分。
关键词: DNA疫苗,pVAX1-rv1419 DNA,免疫治疗,结核分枝杆菌,Rv1419 protein,免疫。
Current Gene Therapy
Title:Immunogenicity and Therapeutic Effects of pVAX1-rv1419 DNA from Mycobacterium tuberculosis
Volume: 16 Issue: 4
Author(s): Yan Liang, Xiaoyan Zhang, Li Xiao, Xuejuan Bai, Xiaomei Wang, Yourong Yang, Junxian Zhang, Jinying Song, Yinping Liu and Ning Li, Xueqiong Wu
Affiliation:
关键词: DNA疫苗,pVAX1-rv1419 DNA,免疫治疗,结核分枝杆菌,Rv1419 protein,免疫。
摘要: Background: Tuberculosis (TB) is threatening disease in China and new therapeutic agents and regimens to treat TB are urgently needed.
Objective: In this study, a DNA vaccine expressing Mycobacterium tuberculosis (MTB) Rv1419 antigen was constructed and its immunogenicity and therapeutic effects were evaluated. Method: Normal mice and TB model mice were immunized intramuscularly three times at two-week intervals with saline, plasmid vector pVAX1, M. vaccae vaccine, pVAX1- ag85a (rv3804c) DNA or pVAX1-rv1419 DNA, respectively. Results: At three weeks after the last immunization, flow cytometry showed a higher proportion of CD4+ T cells expressing IFN-γ (Th1) in response to Rv1419 protein in blood from the pVAX1- rv1419 DNA group compared with the saline and vector groups (P<0.05), suggesting a predominant Th1 immune response. Live bacterial loads in lungs and spleens were lower by 0.41 log10 in the pVAX1- rv1419 DNA group than in the saline controls. In addition, pathological changes in the lungs of the DNA vaccinated groups were less. These results suggest that pVAX1- rv1419 DNA could be effective for the treatment of TB, significantly increasing the Th1-type cellular immune response, and inhibiting the growth of MTB. Conclusion: Therefore pVAX1- rv1419 DNA is a candidate for inclusion in a therapeutic combination DNA vaccine against TB.Export Options
About this article
Cite this article as:
Yan Liang, Xiaoyan Zhang, Li Xiao, Xuejuan Bai, Xiaomei Wang, Yourong Yang, Junxian Zhang, Jinying Song, Yinping Liu and Ning Li, Xueqiong Wu , Immunogenicity and Therapeutic Effects of pVAX1-rv1419 DNA from Mycobacterium tuberculosis, Current Gene Therapy 2016; 16 (4) . https://dx.doi.org/10.2174/1566523216666161102170123
DOI https://dx.doi.org/10.2174/1566523216666161102170123 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Utility of Mycobacterium w Vaccine in Control of Tuberculosis
Current Respiratory Medicine Reviews Design of Fucoidan Functionalized - Iron Oxide Nanoparticles for Biomedical Applications
Current Drug Delivery Inhibitors of Bacterial Transcription are Compounds for Potent Antimicrobial Drugs
Current Pharmaceutical Biotechnology Anionic Antimicrobial Peptides from Eukaryotic Organisms
Current Protein & Peptide Science Host-Pathogen Interactions in Latent Mycobacterium tuberculosis Infection: Identification of New Targets for Tuberculosis Intervention
Endocrine, Metabolic & Immune Disorders - Drug Targets Design, Synthesis and In Vitro Biological Evaluation of Pyridine, Thiadazole, Benzimidazole and Acetyl Thiophene Analogues as Anti Tubercular Agents Targeting Enzyme Inh A
Current Computer-Aided Drug Design Synthesis and Biological Evaluation of Naphthalene-1,4-dione Derivatives as Potent Antimycobacterial Agents
Medicinal Chemistry Molecular Docking Algorithms
Current Drug Targets Role of C-Type Lectins in Mycobacterial Infections
Current Drug Targets The GFP Viability Assay for Cryobiology Applications: A Mechanistic Understanding
Current Tissue Engineering (Discontinued) Alternative Nucleophilic Residues in Intein Catalysis of Protein Splicing
Protein & Peptide Letters Role of Open Source Tools and Resources in Virtual Screening for Drug Discovery
Combinatorial Chemistry & High Throughput Screening Preparation and Characterization of Solid Lipid Nanoparticles-A Review
Current Drug Discovery Technologies Leishmaniasis: Prevention, Parasite Detection and Treatment
Current Medicinal Chemistry Benzothiazole: A Versatile and Multitargeted Pharmacophore in the Field of Medicinal Chemistry
Letters in Organic Chemistry Pharmacogenetics Research Developments in Africa: A Focus on Malawi
Current Pharmacogenomics and Personalized Medicine Ascaris lumbricoides: An Overview of Therapeutic Targets
Infectious Disorders - Drug Targets Prominence of Oxidative Stress in the Management of Anti-tuberculosis Drugs Related Hepatotoxicity
Drug Metabolism Letters Entropy Model for Multiplex Drug-Target Interaction Endpoints of Drug Immunotoxicity
Current Topics in Medicinal Chemistry Predicting Protein-Ligand Binding Sites Based on an Improved Geometric Algorithm
Protein & Peptide Letters